OUE LIPPO HEALTHCARE LTD (5WA) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of OUE LIPPO HEALTHCARE LTD S$0.10, price S$0.05, upside +112.1%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch OUE LIPPO HEALTHCARE LTD for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
OUE Healthcare Limited, an investment holding company, owns, operates, and invests in healthcare businesses in Singapore, China, Myanmar, Indonesia, and Japan. It operates through Healthcare Operations, Healthcare Assets, Properties Under Development, and Investments segments.
Show more
OUE Healthcare Limited, an investment holding company, owns, operates, and invests in healthcare businesses in Singapore, China, Myanmar, Indonesia, and Japan. It operates through Healthcare Operations, Healthcare Assets, Properties Under Development, and Investments segments. The company is involved in the operation of hospitals and clinics; supply of medical equipment and pharmaceutical products; and rental of investment properties and owned assets. It also engages in the development of medical facilities, healthcare-related assets, and integrated mixed-used projects; and investment in real estate investment trusts and properties. The company was formerly known as OUE Lippo Healthcare Limited and changed its name to OUE Healthcare Limited in April 2023. The company was founded in 2010 and is headquartered in Singapore. OUE Healthcare Limited is a subsidiary of OUE Limited.
Stock analysis
OUE LIPPO HEALTHCARE LTD (5WA) currently trades at 0.0480 SGD, while our model-based Fair Value estimate is 0.1018 SGD, implying the stock looks roughly 52.8% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 0.2100 SGD per share, and 12 of the 13 models we run sit above the 0.0480 SGD price.
Bear case: the Asset-Based group reads lowest at 0.0400 SGD, and 1 of the 13 models stay below the price. Evidence for this calculation is low.
Scenario range: 0.0922 SGD (bear) to 0.1306 SGD (bull), the price of 0.0480 SGD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
OUE LIPPO HEALTHCARE LTD reported revenue of 152M SGD in FY2025 versus 19.7M SGD in FY2021, a compound +66.8%/yr. Reported net income was −16.9M SGD in FY2025.
Key figures
Market cap 213M SGD (≈ $166M) · P/S ratio 1.40 · EPS (TTM) −0.0100 SGD · Dividend yield 0.8% · Net margin −11.1% · Return on equity −1.6% · Return on assets (EBIT) 5.0% · Operating margin 49.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 2% below its 52-week high and 100% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 112%, 5WA screens cheaper than that median.
Fair Value models
Bear 0.0922 SGDFair Value 0.1018 SGDBull 0.1306 SGD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+50.1%
Start year 2020 (pandemic). Over 10 years: +13.0% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−11.7% (2018) → 57.0% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about +3.3% a year for the price.
Compare OUE LIPPO HEALTHCARE LTD with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 244 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside+112.1% · Top 25%
Profitability
Return on assets3.6% · Below median
Net margin (TTM)−19.5% · Bottom 25%
Operating margin (TTM)49.7% · Top 25%
Growth and dividend
Revenue growth0.2% · Below median
Dividend yield (TTM)0.8% · Below median
Balance sheet
Debt / equity1.17× · Highest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is OUE LIPPO HEALTHCARE LTD (5WA) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of 0.1018 SGD versus a price of 0.0480 SGD, about +112% upside (undervalued).
What is the fair value of 5WA?
Our model-based fair value for OUE LIPPO HEALTHCARE LTD is 0.1018 SGD (as of Oct 2, 2026), built from audited fundamentals. The current price: 0.0480 SGD.
What is the quality score of 5WA?
OUE LIPPO HEALTHCARE LTD has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for OUE LIPPO HEALTHCARE LTD (5WA)?
Our model-based price target is the fair value of 0.1018 SGD (as of Oct 2, 2026) from 14 valuation models. Cautious scenario 0.0922 SGD, optimistic scenario 0.1306 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the OUE LIPPO HEALTHCARE LTD stock forecast for 2026?
Our models put fair value at 0.1018 SGD, about +112% upside versus a price of 0.0480 SGD (undervalued). Cautious scenario 0.0922 SGD, optimistic scenario 0.1306 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of OUE LIPPO HEALTHCARE LTD (5WA)?
OUE LIPPO HEALTHCARE LTD reported trailing-twelve-month revenue of about 153M SGD (latest available figure, as of Oct 2, 2026).
Does OUE LIPPO HEALTHCARE LTD pay a dividend?
OUE LIPPO HEALTHCARE LTD currently shows a dividend yield of about 0.78% relative to its recent price (as of Oct 2, 2026).
What growth is priced into OUE LIPPO HEALTHCARE LTD (5WA)?
For today's price to be fair in a discounted-cash-flow model, OUE LIPPO HEALTHCARE LTD would have to grow free cash flow by +5.4 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +50.1 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of 5WA use?
Our models discount OUE LIPPO HEALTHCARE LTD at 11.0 %: a base by market capitalisation (micro), damped by beta 0.44, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For OUE LIPPO HEALTHCARE LTD that is +5.4 % per year a year over ten years, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has OUE LIPPO HEALTHCARE LTD (5WA) delivered so far?
Over the past 5 years revenue at OUE LIPPO HEALTHCARE LTD grew +50.1 % a year. The price currently implies +5.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of OUE LIPPO HEALTHCARE LTD (5WA) growing?
The median revenue growth in the sector is +4.7 % a year. That is the yardstick for the growth priced into OUE LIPPO HEALTHCARE LTD (+5.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of OUE LIPPO HEALTHCARE LTD (5WA)?
The free-cash-flow yield on the price is 23.94 %: that much free cash flow OUE LIPPO HEALTHCARE LTD produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of OUE LIPPO HEALTHCARE LTD (5WA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For OUE LIPPO HEALTHCARE LTD it is 0.1018 SGD per share (as of Oct 2, 2026), against a price of 0.0480 SGD. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is OUE LIPPO HEALTHCARE LTD stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 5WA trades below its calculated fair value: price 0.0480 SGD, fair value 0.1018 SGD, a gap of about +112% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 5WA?
No. The price is what the market pays today (0.0480 SGD); the fair value is what the company's own numbers justify (0.1018 SGD). For OUE LIPPO HEALTHCARE LTD the two are 0.0538 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is OUE LIPPO HEALTHCARE LTD worth?
The market values OUE LIPPO HEALTHCARE LTD at about 213M SGD (market capitalisation, as of Oct 2, 2026). Per share that is 0.0480 SGD; our models calculate a fair value of 0.1018 SGD per share.
What do the bullish and bearish scenarios say about 5WA?
Our models span a range for OUE LIPPO HEALTHCARE LTD: cautious scenario 0.0922 SGD, base 0.1018 SGD, optimistic 0.1306 SGD per share (as of Oct 2, 2026, price 0.0480 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of OUE LIPPO HEALTHCARE LTD (5WA)?
Balance-sheet figures for OUE LIPPO HEALTHCARE LTD (as of Oct 2, 2026): return on equity −1.6%, debt of 1.17 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 5WA from its 52-week high?
OUE LIPPO HEALTHCARE LTD trades at 0.0480 SGD, about 2% below its 52-week high of 0.0490 SGD and 100% above the low of 0.0240 SGD (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of 0.1018 SGD is for.
Which stocks are comparable to OUE LIPPO HEALTHCARE LTD?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is OUE LIPPO HEALTHCARE LTD stock attractive at the current price?
The data as of Oct 2, 2026: price 0.0480 SGD, calculated fair value 0.1018 SGD (+112%), Quality Score 53/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 5WA calculated?
We run OUE LIPPO HEALTHCARE LTD through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.1018 SGD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. OUE LIPPO HEALTHCARE LTD currently trades 53 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of OUE LIPPO HEALTHCARE LTD (5WA)?
The closing price on Oct 1, 2026 was 0.0480 SGD. Our model-based fair value is 0.1018 SGD, about +112% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with OUE LIPPO HEALTHCARE LTD right now?
The price is below even our cautious bear case (0.0922 SGD). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (53/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of OUE LIPPO HEALTHCARE LTD
How large is the market capitalisation of OUE LIPPO HEALTHCARE LTD (5WA)?
The market capitalisation of OUE LIPPO HEALTHCARE LTD is 213M SGD (≈ $166M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of OUE LIPPO HEALTHCARE LTD (5WA)?
The price-to-sales ratio of OUE LIPPO HEALTHCARE LTD is 1.40 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of OUE LIPPO HEALTHCARE LTD (5WA)?
Earnings per share at OUE LIPPO HEALTHCARE LTD are −0.0100 SGD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of OUE LIPPO HEALTHCARE LTD (5WA)?
The dividend yield of OUE LIPPO HEALTHCARE LTD is 0.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of OUE LIPPO HEALTHCARE LTD (5WA)?
The net margin of OUE LIPPO HEALTHCARE LTD is −11.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of OUE LIPPO HEALTHCARE LTD (5WA)?
The return on equity (ROE) of OUE LIPPO HEALTHCARE LTD is −1.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of OUE LIPPO HEALTHCARE LTD (5WA)?
On an EBIT basis the return on assets of OUE LIPPO HEALTHCARE LTD is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of OUE LIPPO HEALTHCARE LTD (5WA)?
The operating margin of OUE LIPPO HEALTHCARE LTD is 49.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at OUE LIPPO HEALTHCARE LTD (5WA)?
Revenue at OUE LIPPO HEALTHCARE LTD is growing +0.2% versus a year earlier (3y avg +8.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at OUE LIPPO HEALTHCARE LTD (5WA)?
Earnings per share at OUE LIPPO HEALTHCARE LTD are growing −75.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does OUE LIPPO HEALTHCARE LTD (5WA) carry?
The net debt of OUE LIPPO HEALTHCARE LTD is 465M SGD (fiscal year 2025, ≈ 9.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch OUE LIPPO HEALTHCARE LTD in the live analysis
One click puts OUE LIPPO HEALTHCARE LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
